Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Black Diamond Therapeutics Inc's Business Segments
Black Diamond Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2025
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 70
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2025
- Reportable100%
Revenue by Reportable Segment - Q1 FY2025
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 70 | 100% |
Description of Black Diamond Therapeutics Inc
Black Diamond Therapeutics Inc is a biotechnology company that focuses on precision medicine approaches to develop targeted therapies for patients with genetically defined cancers. The company was founded in 2014 in Cambridge, Massachusetts, United States.
Black Diamond's mission is to discover and develop small molecule drugs that target oncogenic driver mutations, which are specific genetic alterations that drive tumor growth and survival. By targeting these driver mutations, the company aims to provide more effective and personalized treatment options for cancer patients.
The company's proprietary platform, called Mutation-Allostery-Pharmacology (MAP), guides the discovery and design of novel small molecules that can selectively target specific mutant proteins. This approach leverages structure-based drug design and protein engineering techniques to identify compounds that can bind and inhibit the mutant proteins while sparing the corresponding wild-type proteins that are essential for normal cellular function.
Black Diamond has a diverse pipeline of investigational therapies that target different oncogenic drivers across multiple cancer types. Their lead product candidate, BDTX-189, is an orally available small molecule inhibitor that targets a broad range of frequently occurring and clinically validated kinase mutations. This therapy is currently being evaluated in multiple Phase 1/2 clinical trials for advanced solid tumors.
In addition to BDTX-189, Black Diamond has several other preclinical programs in their pipeline targeting specific oncogenic driver gene mutations, including KRAS and NRAS mutations.
The company collaborates with academic institutions, research organizations, and other biopharmaceutical companies to accelerate the discovery and development of precision therapies. Black Diamond has established collaborations with multiple key stakeholders in the field of cancer research and drug development to leverage their expertise and resources.
Black Diamond's team includes experienced scientists, clinicians, and industry leaders who are dedicated to advancing precision oncology. They combine their scientific expertise in cancer biology, drug discovery, and clinical development to drive the company's innovative research programs.
Overall, Black Diamond Therapeutics Inc is at the forefront of precision medicine, utilizing its MAP platform to develop targeted therapies that exploit the unique genetic vulnerabilities of cancer cells. By focusing on genetically defined cancers, the company aims to revolutionize cancer treatment by providing personalized and more effective therapies for patients in need.
Black Diamond's mission is to discover and develop small molecule drugs that target oncogenic driver mutations, which are specific genetic alterations that drive tumor growth and survival. By targeting these driver mutations, the company aims to provide more effective and personalized treatment options for cancer patients.
The company's proprietary platform, called Mutation-Allostery-Pharmacology (MAP), guides the discovery and design of novel small molecules that can selectively target specific mutant proteins. This approach leverages structure-based drug design and protein engineering techniques to identify compounds that can bind and inhibit the mutant proteins while sparing the corresponding wild-type proteins that are essential for normal cellular function.
Black Diamond has a diverse pipeline of investigational therapies that target different oncogenic drivers across multiple cancer types. Their lead product candidate, BDTX-189, is an orally available small molecule inhibitor that targets a broad range of frequently occurring and clinically validated kinase mutations. This therapy is currently being evaluated in multiple Phase 1/2 clinical trials for advanced solid tumors.
In addition to BDTX-189, Black Diamond has several other preclinical programs in their pipeline targeting specific oncogenic driver gene mutations, including KRAS and NRAS mutations.
The company collaborates with academic institutions, research organizations, and other biopharmaceutical companies to accelerate the discovery and development of precision therapies. Black Diamond has established collaborations with multiple key stakeholders in the field of cancer research and drug development to leverage their expertise and resources.
Black Diamond's team includes experienced scientists, clinicians, and industry leaders who are dedicated to advancing precision oncology. They combine their scientific expertise in cancer biology, drug discovery, and clinical development to drive the company's innovative research programs.
Overall, Black Diamond Therapeutics Inc is at the forefront of precision medicine, utilizing its MAP platform to develop targeted therapies that exploit the unique genetic vulnerabilities of cancer cells. By focusing on genetically defined cancers, the company aims to revolutionize cancer treatment by providing personalized and more effective therapies for patients in need.
Black Diamond Therapeutics Inc. is a prominent biopharmaceutical company concentrating on the discovery and development of targeted therapies tailored for cancer patients. The foundation of their approach lies in precision oncology, wherein they harness innovations to create personalized treatment options specifically for patients with genetically defined cancers. The companys extensive offerings can be segmented into various distinctive categories, each with its own products and services meticulously designed to meet the diverse needs arising from different cancer types and their associated genetic alterations.
Segments:
1. Oncology Research and Development:
Black Diamond Therapeutics boasts a dedicated and interdisciplinary research and development team that delves deep into the genetic underpinnings of cancers. Their primary focus is on solid tumors, where they investigate the various molecular mechanisms that lead to tumorigenesis. This segment involves identifying and understanding genetic alterations that drive cancer growth, forming the basis for the companys innovative therapeutic strategies.
Products and Services:
1. Small Molecule Therapies:
Black Diamond Therapeutics specializes in the development of small molecule drugs. These therapeutics are intricately designed to target specific oncogenic driver mutations and genetic alterations, effectively inhibiting the proliferation and survival of cancer cells. By focusing on molecular precision, these therapies aim to minimize collateral damage to healthy cells, thereby enhancing treatment efficacy while mitigating adverse effects. Each drug is tailored to interact with particular pathways activated by genetic mutations, delivering a precise attack on cancer cells.
2. Mutation-Altering Therapies:
One of the pioneering areas of Black Diamond Therapeutics is their mutation-altering therapies. This innovative approach seeks to selectively modify the genetic mutations that instigate cancer growth by correcting the altered genetic codes responsible for tumor development. This therapeutic modality aims not only to restore normal cellular functions but also to impede tumor growth and potentially overcome resistance to existing treatments, thereby expanding the arsenal available to oncologists treating challenging patient cases.
3. Precision Medicine Solutions:
Recognizing the critical importance of tailoring treatment to individual patient profiles, Black Diamond Therapeutics provides precision medicine solutions. Collaborating with diagnostic and genetic testing companies, the company enables comprehensive genetic profiling of tumor samples from patients. This profiling allows clinicians to identify the most suitable therapeutic options based on the unique genetic landscape of a patients cancer. By matching patients with therapies most likely to be effective for their specific genetic makeup, the company enhances treatment efficacy and patient outcomes.
4. Clinical Trials:
The commitment to advancing cancer treatment is underscored by Black Diamond Therapeuticss extensive clinical trial programs. They conduct rigorous evaluations of their therapies safety, efficacy, and tolerability through trials that are often conducted in partnership with leading medical centers and research institutions globally. These trials not only provide essential data to support regulatory approvals but also offer patients access to pioneering treatments that are not yet widely available. Participants in these studies contribute to the evolving landscape of cancer therapeutics, ensuring that new treatment options become available to future patients.
5. Patient Support Programs:
Understanding the challenges faced by patients undergoing cancer treatment, Black Diamond Therapeutics emphasizes the importance of patient support throughout the treatment journey. The company provides a range of support programs, including educational resources to inform patients about their conditions and treatment options, access to counseling services to help manage the emotional aspects of cancer care, and financial assistance initiatives to ensure that patients can afford their therapies. Through these programs, Black Diamond Therapeutics aims to alleviate some of the burdens associated with cancer treatment, fostering a supportive environment for patients and their families.
Conclusion:
In summary, Black Diamond Therapeutics Inc. stands at the forefront of biopharmaceutical innovation with a strong commitment to developing targeted therapies for cancer. Their segments and offerings, including small molecules, mutation-altering therapies, precision medicine solutions, clinical trials, and comprehensive patient support programs, collectively aim to transform cancer care. By addressing the specific genetic alterations characteristic of various cancers, the company is dedicated to improving treatment outcomes and enhancing the quality of life for cancer patients. Through their innovative approach, Black Diamond Therapeutics is setting new standards in the field of oncology.
Segments:
1. Oncology Research and Development:
Black Diamond Therapeutics boasts a dedicated and interdisciplinary research and development team that delves deep into the genetic underpinnings of cancers. Their primary focus is on solid tumors, where they investigate the various molecular mechanisms that lead to tumorigenesis. This segment involves identifying and understanding genetic alterations that drive cancer growth, forming the basis for the companys innovative therapeutic strategies.
Products and Services:
1. Small Molecule Therapies:
Black Diamond Therapeutics specializes in the development of small molecule drugs. These therapeutics are intricately designed to target specific oncogenic driver mutations and genetic alterations, effectively inhibiting the proliferation and survival of cancer cells. By focusing on molecular precision, these therapies aim to minimize collateral damage to healthy cells, thereby enhancing treatment efficacy while mitigating adverse effects. Each drug is tailored to interact with particular pathways activated by genetic mutations, delivering a precise attack on cancer cells.
2. Mutation-Altering Therapies:
One of the pioneering areas of Black Diamond Therapeutics is their mutation-altering therapies. This innovative approach seeks to selectively modify the genetic mutations that instigate cancer growth by correcting the altered genetic codes responsible for tumor development. This therapeutic modality aims not only to restore normal cellular functions but also to impede tumor growth and potentially overcome resistance to existing treatments, thereby expanding the arsenal available to oncologists treating challenging patient cases.
3. Precision Medicine Solutions:
Recognizing the critical importance of tailoring treatment to individual patient profiles, Black Diamond Therapeutics provides precision medicine solutions. Collaborating with diagnostic and genetic testing companies, the company enables comprehensive genetic profiling of tumor samples from patients. This profiling allows clinicians to identify the most suitable therapeutic options based on the unique genetic landscape of a patients cancer. By matching patients with therapies most likely to be effective for their specific genetic makeup, the company enhances treatment efficacy and patient outcomes.
4. Clinical Trials:
The commitment to advancing cancer treatment is underscored by Black Diamond Therapeuticss extensive clinical trial programs. They conduct rigorous evaluations of their therapies safety, efficacy, and tolerability through trials that are often conducted in partnership with leading medical centers and research institutions globally. These trials not only provide essential data to support regulatory approvals but also offer patients access to pioneering treatments that are not yet widely available. Participants in these studies contribute to the evolving landscape of cancer therapeutics, ensuring that new treatment options become available to future patients.
5. Patient Support Programs:
Understanding the challenges faced by patients undergoing cancer treatment, Black Diamond Therapeutics emphasizes the importance of patient support throughout the treatment journey. The company provides a range of support programs, including educational resources to inform patients about their conditions and treatment options, access to counseling services to help manage the emotional aspects of cancer care, and financial assistance initiatives to ensure that patients can afford their therapies. Through these programs, Black Diamond Therapeutics aims to alleviate some of the burdens associated with cancer treatment, fostering a supportive environment for patients and their families.
Conclusion:
In summary, Black Diamond Therapeutics Inc. stands at the forefront of biopharmaceutical innovation with a strong commitment to developing targeted therapies for cancer. Their segments and offerings, including small molecules, mutation-altering therapies, precision medicine solutions, clinical trials, and comprehensive patient support programs, collectively aim to transform cancer care. By addressing the specific genetic alterations characteristic of various cancers, the company is dedicated to improving treatment outcomes and enhancing the quality of life for cancer patients. Through their innovative approach, Black Diamond Therapeutics is setting new standards in the field of oncology.